Cover Image
市場調查報告書

Pharmicell Co., Ltd. - 產品平台分析

Pharmicell Co., Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 308913
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Pharmicell Co., Ltd. - 產品平台分析 Pharmicell Co., Ltd. - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 30 Pages
簡介

Pharmicell Co., Ltd. 是總公司設立於韓國的生物科技企業,正在開發·商品化針對癌症及腦神經系疾病,心臟疾病的幹細胞治療藥。除此以外,該公司尚經手幹細胞銀行及血庫,諮詢,醫藥品受託製造,細胞培養基及細胞株等服務。

本報告提供Pharmicell Co., Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

目錄

Pharmicell Co., Ltd. 的基本資料

  • Pharmicell Co., Ltd. 概要
  • 主要資訊
  • 企業資料

Pharmicell Co., Ltd. :R&D概要

  • 主要的治療範圍

Pharmicell Co., Ltd. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Pharmicell Co., Ltd. :開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Pharmicell Co., Ltd. :藥物簡介

  • Cerecellgram-Stroke
  • Cerecellgram-Spine
  • Livercellgram
  • Cerecellgram for Parkinson's Disease
  • Immunocellgram for Cancer
  • Immunocellgram for Graft Versus Host Disease
  • Cellgram for Severe Lower Limb Ischemia
  • Immpocellgram
  • Cellgram for Severe Hard of Hearing
  • Lungcellgram

Pharmicell Co., Ltd. :開發平台分析

  • 各給藥途徑
  • 各分子類型

Pharmicell Co., Ltd. :最新的開發平台資訊

Pharmicell Co., Ltd. :開發暫停中的計劃

Pharmicell Co., Ltd. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07418CDB

Summary

Global Markets Direct's, 'Pharmicell Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Pharmicell Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharmicell Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Pharmicell Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Pharmicell Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Pharmicell Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Pharmicell Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Pharmicell Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Pharmicell Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Pharmicell Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharmicell Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Pharmicell Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Pharmicell Co., Ltd. Snapshot
    • Pharmicell Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Pharmicell Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Pharmicell Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Pharmicell Co., Ltd. - Pipeline Products Glance
    • Pharmicell Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Pharmicell Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Pharmicell Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Pharmicell Co., Ltd. - Drug Profiles
    • Cerecellgram-Stroke
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cerecellgram-Spine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Livercellgram
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cerecellgram for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Immunocellgram for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Immunocellgram for Graft Versus Host Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellgram for Severe Lower Limb Ischemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Immpocellgram
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellgram for Severe Hard of Hearing
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lungcellgram
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pharmicell Co., Ltd. - Pipeline Analysis
    • Pharmicell Co., Ltd. - Pipeline Products by Route of Administration
    • Pharmicell Co., Ltd. - Pipeline Products by Molecule Type
  • Pharmicell Co., Ltd. - Recent Pipeline Updates
  • Pharmicell Co., Ltd. - Dormant Projects
  • Pharmicell Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Pharmicell Co., Ltd., Key Information
  • Pharmicell Co., Ltd., Key Facts
  • Pharmicell Co., Ltd. - Pipeline by Indication, 2015
  • Pharmicell Co., Ltd. - Pipeline by Stage of Development, 2015
  • Pharmicell Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Pharmicell Co., Ltd. - Phase III, 2015
  • Pharmicell Co., Ltd. - Phase II, 2015
  • Pharmicell Co., Ltd. - Phase I, 2015
  • Pharmicell Co., Ltd. - Preclinical, 2015
  • Pharmicell Co., Ltd. - Pipeline by Route of Administration, 2015
  • Pharmicell Co., Ltd. - Pipeline by Molecule Type, 2015
  • Pharmicell Co., Ltd. - Recent Pipeline Updates, 2015
  • Pharmicell Co., Ltd. - Dormant Developmental Projects,2015
  • Pharmicell Co., Ltd., Other Locations

List of Figures

  • Pharmicell Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Pharmicell Co., Ltd. - Pipeline by Stage of Development, 2015
  • Pharmicell Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Pharmicell Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Pharmicell Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
Back to Top